127 related articles for article (PubMed ID: 27428073)
1. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
Caballero-Baños M; Benitez-Ribas D; Tabera J; Varea S; Vilana R; Bianchi L; Ayuso JR; Pagés M; Carrera G; Cuatrecasas M; Martin-Richard M; Cid J; Lozano M; Castells A; García-Albéniz X; Maurel J; Vilella R
Eur J Cancer; 2016 Sep; 64():167-74. PubMed ID: 27428073
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.
Lin T; Song C; Chuo DY; Zhang H; Zhao J
Tumour Biol; 2016 Apr; 37(4):4367-72. PubMed ID: 26499782
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
Kang JH; Lee SI; Lim DH; Park KW; Oh SY; Kwon HC; Hwang IG; Lee SC; Nam E; Shin DB; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
J Clin Oncol; 2012 May; 30(13):1513-8. PubMed ID: 22412140
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
Kim TW; Elme A; Kusic Z; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Bilic A; Manojlovic N; Dong J; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Br J Cancer; 2016 Nov; 115(10):1206-1214. PubMed ID: 27736842
[TBL] [Abstract][Full Text] [Related]
5. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination of patients with metastatic colorectal cancer.
Burgdorf SK
Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
[TBL] [Abstract][Full Text] [Related]
8. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
10. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
11. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
[TBL] [Abstract][Full Text] [Related]
13. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thuss-Patience PC; Kretzschmar A; Bichev D; Deist T; Hinke A; Breithaupt K; Dogan Y; Gebauer B; Schumacher G; Reichardt P
Eur J Cancer; 2011 Oct; 47(15):2306-14. PubMed ID: 21742485
[TBL] [Abstract][Full Text] [Related]
14. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
[TBL] [Abstract][Full Text] [Related]
15. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
16. FDA drug approval summary: panitumumab (Vectibix).
Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
[TBL] [Abstract][Full Text] [Related]
17. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
18. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Español-Rego M; Fernández-Martos C; Elez E; Foguet C; Pedrosa L; Rodríguez N; Ruiz-Casado A; Pineda E; Cid J; Cabezón R; Oliveres H; Lozano M; Ginés A; García-Criado A; Ayuso JR; Pagés M; Cuatrecasas M; Torres F; Thomson T; Cascante M; Benítez-Ribas D; Maurel J
Cancer Immunol Immunother; 2023 Apr; 72(4):827-840. PubMed ID: 36083313
[TBL] [Abstract][Full Text] [Related]
19. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.
Liu KJ; Chao TY; Chang JY; Cheng AL; Ch'ang HJ; Kao WY; Wu YC; Yu WL; Chung TR; Whang-Peng J
J Biomed Sci; 2016 Aug; 23(1):64. PubMed ID: 27558635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]